Wechselwirkungen von Choriogonadotropin alfa
Choriogonadotropin alfa (Ovidrel) hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 60 dokumentierte Wechselwirkungen: 37 schwerwiegende, 23 mittelschwere, 0 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.
Wechselwirkungen laut Fachinformation
Schwerwiegende Wechselwirkungen (37)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (Fachinformation zu Choriogonadotropin alfa, Gegenanzeigen)
Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (Fachinformation zu Choriogonadotropin alfa, Gegenanzeigen)
Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (Fachinformation zu Choriogonadotropin alfa, Gegenanzeigen)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (Fachinformation zu Choriogonadotropin alfa, Gegenanzeigen)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (Fachinformation zu Choriogonadotropin alfa, Gegenanzeigen)
Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (Fachinformation zu Choriogonadotropin alfa, Gegenanzeigen)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Mittelschwere Wechselwirkungen (23)
PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (Fachinformation zu Choriogonadotropin alfa, Vorsichtsmaßnahmen)
- ChoriongonadotropinMittelschwer
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (Fachinformation zu Choriogonadotropin alfa, Vorsichtsmaßnahmen)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (Fachinformation zu Choriogonadotropin alfa, Vorsichtsmaßnahmen)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (Fachinformation zu Choriogonadotropin alfa, Vorsichtsmaßnahmen)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
The indices most generally used are as follows: A rise in basal body temperature Increase in serum progesterone and Menstruation following a shift in basal body temperature Urinary or serum luteinizing hormone (LH) rise When used in conjunction with the indices of progesterone production, sonographic visualization of the ovaries will assist in determining if… (Fachinformation zu Choriogonadotropin alfa, Vorsichtsmaßnahmen)
PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (Fachinformation zu Choriogonadotropin alfa, Vorsichtsmaßnahmen)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)
Prüfen Sie Choriogonadotropin alfa gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.
Im Wechselwirkungscheck öffnenKeine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.